Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

48-week investigational regimen yielded nearly double SVR rate compared to standard of care

Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting

COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of the HCV SPRINT-1 study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin, significantly increased sustained virologic response (SVR)(1) rates with 28 and 48 weeks of therapy compared to current standard of care, peginterferon and ribavirin for 48 weeks (control group). The results from this Phase II study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.(2) Genotype 1 is the most common and hardest to treat form of hepatitis C.

In Part I of the study, a 48-week boceprevir regimen achieved a 75 percent SVR rate (n=77/103) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) (P/R) followed by the addition of boceprevir (800 mg TID) for 44 weeks (boceprevir P/R lead-in regimen). This represents a near doubling of the 38 percent SVR rate (n=39/104) for patients in the control group (p<0.0001). In a 28-week boceprevir P/R lead-in regimen 56 percent of patients (n=58/103) achieved SVR (p=0.005).(3)

Importantly, the likelihood (predictability) of attaining SVR was greater for patients who received the boceprevir P/R lead-in regimens compared to the no lead-in arms. Of patients in the boceprevir P/R lead-in arms who achieved a rapid virologic response (RVR), 94 percent in the 48-week regimen and 82 percent in the 28-week r
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Ohio , July 24, 2014  As part of ... Cardinal Health will host its annual Pharmacy Ownership Boot Camp ... Business Conference in Washington, D.C. ... the business knowledge and confidence needed to own their own ... has become the industry,s leading event for women pharmacists who ...
(Date:7/24/2014)... , July 24, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, reported interim results ... ASONEP™ is being investigated as a treatment for ... have failed at least one therapy involving a ... more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with ...
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
Breaking Medicine Technology:'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22
... Calif., May 17, 2011 Asante Solutions, Inc. (Asante), ... that the U.S. Food and Drug Administration has granted ... month, the Pearl also received the CE Mark, a ... EU safety, health and environmental requirements. "We ...
... May 17, 2011 The American Association of ... Turnitin for Admissions®, Turnitin®, and iThenticate®, the global ... Turnitin for Admissions service has been selected as ... that use AACP,s Pharmacy College Application Service (PharmCAS) ...
Cached Medicine Technology:Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump 2Pharmacy College Applications Screened Using Turnitin for Admissions 2
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... Cuyahoga County high school students are smoking tobacco products ... according to new data from the Prevention Research Center ... In 2013, more than 22 percent, or one in ... product within the prior 30 days. , Equally surprising ... and hookahs, or water pipes, more than cigarettes ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... funded insurance program for the poor, visit the emergency room ... insured youngsters, a U.S. survey finds. And kids with ... visit for a reason other than a serious medical problem, ... for Disease Control and Prevention. Reliance on ...
(Date:7/24/2014)... - Aristotle said, "Love is composed of a single ... that you and your partner were made in heaven ... new study. , Psychologists observe that people talk ... underlying such diversity are some common themes that frame ... frame considers love as perfect unity ("made for each ...
(Date:7/24/2014)... 2014 The South American air and missile ... 2014 and is expected to register a CAGR of 9.64% ... on tackling internal security issues like drug trafficking. Brazil is ... in the air and missile defense radar market. This is ... in the market for radar systems in terms of costal ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Cuyahoga County high school students smoking at the same rate as adults 2Health News:Cuyahoga County high school students smoking at the same rate as adults 3Health News:Cuyahoga County high school students smoking at the same rate as adults 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:New research: When it hurts to think we were made for each other 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5
... (FHC) has received an initial order for the supply ... AIDS Control Organisation (NACO). ,"The condoms will be ... and distribution will initially be focused on commercial sex ... Pradesh, Karnataka, Maharastra) in India," said a statement issued ...
... A new study has pointed out the alarming incidence of ... more than 25 million people, approximating// to one-fifth of the ... stroke. ,In view of this health threat, the ... in the diet and do more exercise, if these effects ...
... officials, investigating the incidence of fungal infection in Bausch and ... the infection. The only association arrived at is that nearly ... used a lens cleansing solution, manufactured by Bausch and Lomb. ... contact lens and lens solution, feels that the cause of ...
... have revealed that cooked tomatoes contain an ingredient called ... cardiovascular disease// . ,Lycopene, is a bright ... other red fruits. Lycopene is the most common carotenoid ... most potent carotenoid antioxidants. ,Besides tomatoes other ...
... nation’s first test tube babies, both girls, as a testament ... as Agnes and as Jane are overjoyed and are in ... 300,000 Kenyan shillings (?2,275) for the now rather commonplace in ... Louise Brown was born in Oldham, U.K on July 25, ...
... had warned that office workers sit at their computer screens ... of being affected by deep vein thrombosis. ,This ... Bristol almost died after a 12-hour stint in front of ... the first cases in the UK of a growing phenomenon ...
Cached Medicine News:Health News:US Firm To Supply Female Condoms To India 2Health News:Testtube Babies Born in Kenya 2
Inquire...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
... from Berthold Technologies, has been designed ... measurement modes to support academic and ... ratio measurements plus top and bottom ... for any researcher using fluorescence in ...
Medicine Products: